OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Sex X Time Interactions in Lp(a) and LDL-C Response to Evolocumab
Federica Fogacci, Serra İlayda Yerlitaş, Marina Giovannini, et al.
Biomedicines (2023) Vol. 11, Iss. 12, pp. 3271-3271
Open Access | Times Cited: 7
Federica Fogacci, Serra İlayda Yerlitaş, Marina Giovannini, et al.
Biomedicines (2023) Vol. 11, Iss. 12, pp. 3271-3271
Open Access | Times Cited: 7
Showing 7 citing articles:
Lifestyle and Lipoprotein(a) Levels: Does a Specific Counseling Make Sense?
Federica Fogacci, Valentina Di Micoli, Pierre Sabouret, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 3, pp. 751-751
Open Access | Times Cited: 5
Federica Fogacci, Valentina Di Micoli, Pierre Sabouret, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 3, pp. 751-751
Open Access | Times Cited: 5
Cholesterol-Lowering Strategies for Cardiovascular Disease Prevention: The Importance of Intensive Treatment and the Simplification of Medical Therapy
Vincenzo Sucato, Antonella Ortello, Francesco Comparato, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 1882-1882
Open Access | Times Cited: 4
Vincenzo Sucato, Antonella Ortello, Francesco Comparato, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 1882-1882
Open Access | Times Cited: 4
Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention
Vincenzo Sucato, Francesco Comparato, Antonella Ortello, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 5, pp. 460-460
Open Access | Times Cited: 2
Vincenzo Sucato, Francesco Comparato, Antonella Ortello, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 5, pp. 460-460
Open Access | Times Cited: 2
Lipoprotein Metabolism, Dyslipidemia, and Lipid-Lowering Therapy in Women: A Comprehensive Review
Jakub Michał Zimodro, M Mucha, Heiner K. Berthold, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 913-913
Open Access | Times Cited: 2
Jakub Michał Zimodro, M Mucha, Heiner K. Berthold, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 913-913
Open Access | Times Cited: 2
Estimating the Prevalence and Characteristics of Patients Potentially Eligible for Lipoprotein(a)-Lowering Therapies in a Real-World Setting
Arrigo F.G. Cicero, Federica Fogacci, Marina Giovannini, et al.
Biomedicines (2023) Vol. 11, Iss. 12, pp. 3289-3289
Open Access | Times Cited: 5
Arrigo F.G. Cicero, Federica Fogacci, Marina Giovannini, et al.
Biomedicines (2023) Vol. 11, Iss. 12, pp. 3289-3289
Open Access | Times Cited: 5
Safety and Efficacy of PCSK9 Inhibitors in Patients with Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Grafts: A Comparative Retrospective Analysis
Giuseppe Nasso, Claudio Larosa, Francesco Bartolomucci, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 3, pp. 907-907
Open Access | Times Cited: 1
Giuseppe Nasso, Claudio Larosa, Francesco Bartolomucci, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 3, pp. 907-907
Open Access | Times Cited: 1
Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression
Frederick Berro Rivera, Sung Whoy, John Vincent Magalong, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 7, pp. 1103-1121
Closed Access
Frederick Berro Rivera, Sung Whoy, John Vincent Magalong, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 7, pp. 1103-1121
Closed Access
